RecruitingNCT05799118

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Sponsor

Cyprus Institute of Neurology and Genetics

Enrollment

30,000 participants

Start Date

Oct 1, 2022

Study Type

OBSERVATIONAL

Conditions

Sickle Cell Disease Hemoglobinopathies Thalassemia Alpha Thalassemia (beta)

Summary

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying GWAS for people with hemoglobinopathies, sickle cell disease, and other related conditions. The study is currently recruiting participants at 26 locations. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICGWAS

The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.

Locations(26)

Boston Children's Hospital

Boston, Massachusetts, United States

Lucrecia Paím Maternity

Luanda, Angola

University of Buenos Aires

Buenos Aires, Argentina

University Hospitals Leuven

Leuven, Belgium

Universiti Brunei Darussalam

Brunei, Brunei

Larnaca General Hospital

Larnaca, Cyprus

Limassol General Hospital

Limassol, Cyprus

Archbishop Makarios III Hospital

Nicosia, Cyprus

Paphos General Hospital

Paphos, Cyprus

Centre Hospitalier Monkole

Kinshasa, Democratic Republic of the Congo

Rigshospitalet

Copenhagen, Denmark

Hippokrateio Hospital of Athens

Athens, Greece

Laiko General Hospital

Athens, Greece

National and Kapodistrian University of Athens

Athens, Greece

General Hospital of Larissa

Larissa, Greece

Emek Medical Centre

Afula, Israel

University of Turin

Turin, Italy

Ampang Hospital

Ampang, Malaysia

Universiti Kebangsaan Malaysia

Bangi, Malaysia

Universiti Sains Malaysia

Kota Bharu, Malaysia

University of Abuja

Abuja, Nigeria

Kaduna State University

Kaduna, Nigeria

Ahmadu Bello University

Zaria, Nigeria

University of Lahore

Lahore, Pakistan

Centro Hospitalar e Universitário de Coimbra

Coimbra, Portugal

Hospital Clínico San Carlos

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05799118

Related Trials

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

NCT075991761 location

Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)

NCT053839111 location

Uganda Sickle Surveillance Study (US-3)

NCT063018934 locations

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT039378171 location

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226105 locations